Summit Therapeutics Inc.
SMMT
$18.91
-$1.55-7.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.73% | 275.23% | 121.20% | 69.01% | 52.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -14.53% | 199.62% | -688.89% | 63.53% | 84.20% |
| Total Operating Expenses | 81.20% | 184.88% | 182.45% | 161.03% | 176.50% |
| Operating Income | -81.20% | -184.88% | -182.45% | -161.03% | -176.50% |
| Income Before Tax | -67.37% | -164.50% | -310.31% | 91.98% | -90.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.37% | -164.50% | -310.31% | 91.98% | -90.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.37% | -164.50% | -310.31% | 91.98% | -90.17% |
| EBIT | -81.20% | -184.88% | -182.45% | -161.03% | -176.50% |
| EBITDA | -81.29% | -185.23% | -183.15% | -162.32% | -182.86% |
| EPS Basic | -59.00% | -153.77% | -304.27% | 95.68% | 25.43% |
| Normalized Basic EPS | -59.20% | -153.40% | -203.79% | -9.01% | -18.98% |
| EPS Diluted | -71.65% | -162.30% | -326.54% | 95.68% | 27.30% |
| Normalized Diluted EPS | -59.20% | -153.40% | -203.79% | -9.01% | -18.98% |
| Average Basic Shares Outstanding | 5.27% | 4.14% | 1.46% | 85.58% | 155.04% |
| Average Diluted Shares Outstanding | 5.27% | 4.14% | 1.46% | 85.58% | 155.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
